SRNE Stock Recent News
SRNE LATEST HEADLINES
Sorrento Therapeutics (NASDAQ:SRNE) Inc plunged more than 60% after it was revealed the biopharmaceutical company has filed for Chapter 11 bankruptcy protection as its debts mount amid lawsuits. Sorrento and its wholly-owned subsidiary Scintilla Pharmaceuticals Inc have commenced voluntary bankruptcy proceedings in the US Bankruptcy Court for the Southern District of Texas “to protect the company's business and maximize its value,” according to a document filed with the SEC on Monday.
A famed short-seller already had Sorrento Therapeutics in its sights as far back as 2020. That pressure came to a head Monday.
A bankruptcy filing is weighing on the drugmaker's shares today.
Sorrento Therapeutics (NASDAQ: SRNE ) stock is falling on Monday after the company filed for bankruptcy alongside subsidiary Scintilla Pharmaceuticals. A filing with the U.S. Securities and Exchange Commission (SEC) reveals the bankruptcy filing was made with the United States Bankruptcy Court for the Southern District of Texas.
Here's some tips for sustainably investing in penny stocks The post How to Sustainably Invest in Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Shares of Scilex could trade higher due to hedging pressure from large Sorrento short positions. Scilex's equity offering facilities, mean that the price could fall precipitously at any time via company dilution.
Sorrento Therapeutics is on the move following preliminary results from its subsidiary Scilex. Scilex is making money with the company's 1st product to market
Avoid making these penny stocks trading mistakes this year The post Biggest Penny Stocks Trading Mistakes to Avoid in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Sofusa®, a wholly-owned division of Sorrento Therapeutics (Nasdaq: SRNE, “Sorrento”), today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday, November 17, 2022 at 11:30 AM EST.
Sorrento Therapeutics has been in the limelight for all the wrong reasons. Its R&D is just a byproduct of its business.